Immunotherapy regimes dependent on ApoE status
View Patent ↗The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient.
1. A method of treating a disease characterized by Aβ deposits in the brain of patient comprising intravenously or subcutaneously administering an effective regime of a humanized antibody to a population of patients suffering from the disease; wherein the humanized antibody comprises a mature light chain variable region sequence of SEQ ID NO:2 and a mature heavy chain variable region sequence of SEQ ID NO:3, and a human heavy chain constant region of IgG1 isotype with L234A, L235A, and G237A mutations, wherein positions are numbered by the EU numbering system, and thereby treating the disease in the patients, wherein the regime administered to different patients in the population does not depend on the number of ApoE4 alleles present in a patient.
2. The method of claim 1 , wherein the dose is 0.15-1 mg/kg.
3. The method of claim 1 , wherein the dose is 0.15-2 mg/kg.
4. The method of claim 1 , wherein the dosage is 10 mg/kg.
5. The method of claim 1 , further comprising monitoring the patient by MRI for vasogenic edema.
6. The method of claim 1 , wherein the antibody is an L234A, L235A, G237A variant of bapineuzumab.
7. The method of claim 2 , wherein the antibody is an L234A, L235A, G237A variant of bapineuzumab.
8. The method of claim 3 , wherein the antibody is an L234A, L235A, G237A variant of bapineuzumab.
9. The method of claim 5 , wherein the antibody is an L234A, L235A, G237A variant of bapineuzumab.
10. The method of claim 1 , wherein the disease is Alzheimer's disease.
11. The method of claim 6 , wherein the disease is Alzheimer's disease.
12. The method of claim 7 , wherein the disease is Alzheimer's disease.
13. The method of claim 8 , wherein the disease is Alzheimer's disease.
14. The method of claim 9 , wherein the disease is Alzheimer's disease.
15. A method of reducing the risk, lessening the severity or delaying the outset of a disease characterized by Aβ deposits in the brain of patient comprising administering an effective regime of a humanized antibody to a population of patients susceptible to the disease; wherein the humanized antibody comprises a mature light chain variable region sequence of SEQ ID NO:2 and a mature heavy chain variable region sequence of SEQ ID NO:3, and a human heavy chain constant of IgG1 isotype with L234A, L235A, and G237A mutations, wherein positions are numbered by the EU numbering system, thereby reducing the risk, lessening the severity or delaying the outset of the disease in the patients, wherein the regime administered to different patients in the population does not depend on the number of ApoE4 alleles present in a patient.
16. The method of claim 15 , wherein the dose is 0.15-1 mg/kg.
17. The method of claim 15 , wherein the dose is 0.15-2 mg/kg.
18. The method of claim 15 , further comprising monitoring the patient by MRI for vasogenic edema.
19. The method of claim 15 , wherein the antibody is an L234A, L235A, G237A variant of bapineuzumab.
20. The method of claim 16 , wherein the antibody is an L234A, L235A, G237A variant of bapineuzumab.
21. The method of claim 17 , wherein the antibody is an L234A, L235A, G237A variant of bapineuzumab.
22. The method of claim 18 , wherein the antibody is an L234A, L235A, G237A variant of bapineuzumab.
23. The method of claim 15 , wherein the disease is Alzheimer's disease.
24. The method of claim 19 , wherein the disease is Alzheimer's disease.
25. The method of claim 20 , wherein the disease is Alzheimer's disease.
26. The method of claim 21 , wherein the disease is Alzheimer's disease.
27. The method of claim 22 , wherein the disease is Alzheimer's disease.